Biochemical IC50 screen 12 compounds and 1 control for PKM2, PKL and PKR
Ended Purchase Order Awarded Last action
- Contract number
- 75N95C25P00097
- Awardee
-
BPS Bioscience Inc. UEI ZLDNP9C134F3
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,340
Award facts
- Contract value 100% obligated
- $11,340.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
About this award
The National Center for Advancing Translational Sciences (NCATS) awarded a $11,340 firm fixed-price purchase order to BPS Bioscience Inc. for a biochemical IC50 screening study. The contract calls for the vendor to conduct inhibitory concentration testing on twelve compounds plus one control against three protein kinase targets: PKM2, PKL, and PKR. This procurement supports NCATS's mission to accelerate the translation of laboratory discoveries into clinical applications by providing critical drug screening data to identify promising therapeutic candidates. The work is scheduled for completion by September 15, 2026, with performance to be conducted at BPS Bioscience's facility in San Diego, California. No set-aside designation was applied to this contract award.
BPS Bioscience Inc., a specialized manufacturer of high-quality enzymes and biological assay reagents, is well-positioned to deliver this screening service based on its extensive experience supporting NIH research initiatives. The company has established a track record furnishing recombinant kinases and assay kits to federal agencies including the National Cancer Institute and the National Institute on Drug Abuse. This purchase order represents a continuation of BPS Bioscience's role in supporting translational science research and drug discovery efforts across the National Institutes of Health.
Quick answers
Who was awarded contract 75N95C25P00097?
75N95C25P00097 was awarded to BPS Bioscience Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on September 16, 2025.
How much is contract 75N95C25P00097 worth?
The government has obligated $11,340 on 75N95C25P00097.
Was contract 75N95C25P00097 competed?
The extent of competition for 75N95C25P00097 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award